Essential Biomarkers & Genetic Alterations Evaluated
Precision oncology requires rigorous verification of somatic mutations, protein expression, and genomic signatures before finalizing a treatment protocol.
EGFR Mutations (Exon 19 del, L858R, Exon 20 ins)
Directs frontline 3rd-generation TKI therapy (Osimertinib) or bispecific antibodies (Amivantamab) over chemo-immunotherapy.
ALK & ROS1 Gene Rearrangements
Identifies candidates for highly potent, central nervous system-penetrant TKIs (Alectinib, Brigatinib, Lorlatinib).
KRAS G12C Alteration
Directs targeted KRAS inhibitors (Sotorasib, Adagrasib) in patients previously thought to lack targetable alterations.
BRAF V600E, MET Exon 14, RET & NTRK
Actionable oncogenic drivers with FDA-approved targeted oral therapies that achieve 60-80% response rates.
PD-L1 Expression (TPS %)
Guides single-agent immunotherapy (Pembrolizumab, Cemiplimab) for TPS ≥50% versus chemo-immunotherapy combinations for TPS 1-49%.
Critical Treatment Decisions Addressed in Your Review
Our multidisciplinary panel examines your case from medical oncology, surgical, and radiation oncology angles to address these pivotal questions:
SBRT (Stereotactic Radiation) vs Surgical Resection
Assessing cardiopulmonary reserve and tumor location (central vs peripheral) for early Stage I/II NSCLC.
Mediastinal Staging (EBUS-TBNA vs Mediastinoscopy)
Accurate classification of N1 vs N2 lymph node involvement to determine resectability and perioperative immunotherapy candidacy.
Oligometastatic Local Consolidative Therapy
Reviewing whether definitive radiation or surgery to 1-3 distant metastases (brain, adrenal) improves progression-free survival.
Brain Metastasis Management
Evaluating stereotactic radiosurgery (SRS) vs whole brain radiation (WBRT) to preserve neurocognitive function.
Records Required for Lung Cancer Second Opinion
Upload your files online. Our team coordinates directly with your hospital if records are incomplete.
Pathology & Biopsy Reports
Complete histopathology, tumor margin documentation, and formal IHC score sheets.
Raw DICOM Scans
CT, MRI, PET-CT discs or digital cloud download links (not just radiologist text summaries).
Genomic & NGS Panels
FoundationOne, Guardant, Tempus, or specialized assay reports (e.g. Oncotype, Decipher).
Frequently Asked Questions: Lung Cancer
Clear clinical answers regarding diagnostic accuracy, surgical options, and biomarker interpretation.
Related Second Opinion & Diagnostic Services
Cancer decisions intersect pathology, radiology, and adjacent disease subspecialties.
Cancer Pathology Second Opinion
Pathology is the foundational blueprint of every cancer diagnosis, yet it is inherently interpretive. Major peer-reviewed medical studies document that 15% to 30% of second-look pathology reviews uncover diagnostic discordance: benign conditions mistaken for malignant tumors, incorrect tumor staging, missed lymphovascular invasion, or discordant hormone receptor/HER2 status that profoundly alters systemic treatment.
Cancer Radiology Second Opinion
Radiology reports are often produced under high-volume general hospital conditions where subtle oncologic nuances can be overlooked. Up to 20% of expert radiology second opinions identify critical discrepancies: unrecognized liver or peritoneal metastases, missed vascular encasement that alters surgical resectability, or confusion between treatment-induced pseudo-progression and true tumor growth.
Rare Cancer Second Opinion
A rare cancer is defined as fewer than 6 cases per 100,000 individuals annually (e.g. soft tissue sarcomas, gastrointestinal stromal tumors, neuroendocrine neoplasms, adrenocortical carcinoma, salivary gland tumors). In rare malignancies, initial diagnostic discordance rates exceed 35% at general hospitals. A dedicated rare cancer second opinion provides subspecialty histopathologic re-examination, comprehensive RNA fusion sequencing, and compassionate-use trial access.
Complete Second Opinion Guide
Compare multidisciplinary reviews, read about record transfer logistics, and review transparent $450 flat pricing.
Get an Independent Second Opinion on Your Lung Cancer Diagnosis
Upload your biopsy pathology slides, NGS reports, and DICOM scans. Receive a comprehensive multidisciplinary written report and staging audit within 12 to 72 hours.